COVID-19 drug: Hetero Healthcare to supply 20,000 vials of Covifor in India at Rs 5,400 per vial

By: |
Published: June 25, 2020 7:00 AM

Covifor is the first generic brand of Remdesivir, indicated for the treatment of Covid-19 in adults and children, hospitalised with severe symptoms of the disease.

Covifor, to be priced at Rs 5,400 per vial, will be used on critically-affected Covid patients in hospitals.Covifor, to be priced at Rs 5,400 per vial, will be used on critically-affected Covid patients in hospitals. (Representative image)

Followed by the approval from the Drug Controller General of India (DCGI) to market Covifor, the generic of Remdesivir, Hetero Healthcare on Wednesday said it was all set to deliver the first set of 20,000 vials in two lots of 10,000 vials.

One set will be immediately supplied to both corporate and government hospitals in Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra; while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week’s time to meet the emergency requirements.

Covifor, to be priced at Rs 5,400 per vial, will be used on critically-affected Covid patients in hospitals.“The launch of Covifor in India is a significant milestone for all of us. Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating Covid-19 infection rates. We are working closely with the government and medical community to make Covifor quickly accessible to both public and private healthcare centres across the country,” M Srinivasa Reddy, MD, Hetero Healthcare, said in a statement.

Covifor is the first generic brand of Remdesivir, indicated for the treatment of Covid-19 in adults and children, hospitalised with severe symptoms of the disease. The drug is available in 100 mg vial (injectable). It needs to be administered intravenously in hospital’s critical care setting, under the supervision of a registered medical practitioner. Covifor is expected to play a significant role in bringing down the mortality rates, given its proven positive clinical outcomes.

Hetero Healthcare is a group company of Hetero and is engaged in the marketing and distribution of medicines in the India. The company has 11 specialised marketing divisions and has been a market leader in ARV, oncology, anti-flu and anti-bacterials.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covaxin Covid-19 vaccine: ICMR aims for August 15 launch, health experts say “unrealistic deadline”
2In Haryana’s five NCR districts, 14-fold rise in deaths, 7-fold jump in infections in June
3Coronavirus testing cost in Odisha: State caps COVID test fee at Rs 2200